ATE284959T1 - Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung - Google Patents
Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendungInfo
- Publication number
- ATE284959T1 ATE284959T1 AT95925934T AT95925934T ATE284959T1 AT E284959 T1 ATE284959 T1 AT E284959T1 AT 95925934 T AT95925934 T AT 95925934T AT 95925934 T AT95925934 T AT 95925934T AT E284959 T1 ATE284959 T1 AT E284959T1
- Authority
- AT
- Austria
- Prior art keywords
- binding
- mdm2
- disruption
- therapeutic application
- corresponding therapeutic
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 4
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/277,660 US5702908A (en) | 1994-07-20 | 1994-07-20 | Interruption of binding of MDM2 and p53 protein and therapeutic application thereof |
| US08/424,957 US5770377A (en) | 1994-07-20 | 1995-04-19 | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
| PCT/GB1995/001719 WO1996002642A1 (en) | 1994-07-20 | 1995-07-20 | INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE284959T1 true ATE284959T1 (de) | 2005-01-15 |
Family
ID=26958629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95925934T ATE284959T1 (de) | 1994-07-20 | 1995-07-20 | Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5770377A (de) |
| EP (1) | EP0773996B1 (de) |
| JP (2) | JP3961015B2 (de) |
| AT (1) | ATE284959T1 (de) |
| AU (1) | AU684194B2 (de) |
| CA (1) | CA2195533A1 (de) |
| DE (1) | DE69533855T2 (de) |
| NZ (1) | NZ289899A (de) |
| WO (1) | WO1996002642A1 (de) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2738151B1 (fr) * | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
| EP0859956B1 (de) * | 1995-09-18 | 2003-07-02 | Cancer Research Technology Limited | Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen |
| US7083983B2 (en) * | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| GB9620028D0 (en) * | 1996-09-26 | 1996-11-13 | Ludwig Inst Cancer Res | Factors which interact with oncoproteins |
| GB9708092D0 (en) * | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
| GB9708089D0 (en) * | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to stabilising substances in cells |
| US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
| US6372490B1 (en) | 1999-02-23 | 2002-04-16 | Curagen Corporation | Nucleic acid encoding the MDM interacting protein |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US20050245451A1 (en) * | 2000-04-05 | 2005-11-03 | Pincus Matthew R | Peptides selectively lethal to malignant and transformed mammalian cells |
| US20040038902A1 (en) * | 2000-04-05 | 2004-02-26 | Pincus Matthew R. | Peptides selectively lethal to malignant and transformed mammalian cells |
| US6989239B2 (en) * | 2001-06-20 | 2006-01-24 | R.E.D. Laboratories, N.V./S.A. | Methods for diagnosis and treatment of chronic immune diseases |
| US20020169730A1 (en) * | 2001-08-29 | 2002-11-14 | Emmanuel Lazaridis | Methods for classifying objects and identifying latent classes |
| EP1490089A4 (de) * | 2002-03-12 | 2006-08-30 | Univ New York State Res Found | Selektiv letale peptide für maligne und transformierte säugetierzellen |
| US7534861B2 (en) * | 2003-01-10 | 2009-05-19 | Ambergen, Inc. | Compositions and methods for immunoaffinity purification |
| JP4051327B2 (ja) * | 2003-09-19 | 2008-02-20 | 新科實業有限公司 | 垂直磁気記録ヘッドおよびその製造方法、ならびに磁気記録装置 |
| EP1680443B9 (de) * | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Peptide mit stabilisierter alpha-helix und deren verwendungen |
| US7772367B2 (en) * | 2004-01-30 | 2010-08-10 | The Trustees Of Columbia University In The City Of New York | C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof |
| WO2005097820A1 (en) * | 2004-04-06 | 2005-10-20 | Korea Research Institute Of Bioscience And Biotechnology | Peptides for inhibiting mdm2 function |
| DE602004024831D1 (de) * | 2004-04-22 | 2010-02-04 | Ortho Mcneil Pharm Inc | Hdm2-inhibitorkomplexe und verwendungen davon |
| CA2686827C (en) * | 2006-12-14 | 2014-09-16 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| CN109627287A (zh) | 2007-02-23 | 2019-04-16 | 爱勒让治疗公司 | 三唑大环系统 |
| EP2508531B1 (de) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Geheftete Polypeptide |
| EP2224961A1 (de) * | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen |
| BRPI0907754A2 (pt) | 2008-02-08 | 2015-07-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos terapêuticos |
| US20110144303A1 (en) * | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
| US20090326192A1 (en) * | 2008-04-08 | 2009-12-31 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| EP2356139A4 (de) * | 2008-07-23 | 2013-01-09 | Harvard College | Ligieren zusammengehefteter polypeptide |
| CN102203126A (zh) | 2008-09-22 | 2011-09-28 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| EP2376100B1 (de) | 2009-01-14 | 2017-10-25 | Aileron Therapeutics, Inc. | Peptidomimetische makrozyklen |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| KR101220516B1 (ko) * | 2010-01-21 | 2013-01-10 | 연세대학교 산학협력단 | 항-mdm2를 발현하는 인간 성체줄기세포 및 그의 용도 |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| CA3113959A1 (en) | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| EP3782638A1 (de) | 2013-03-13 | 2021-02-24 | President and Fellows of Harvard College | Gestapelte und geheftete polypeptide und verwendungen davon |
| WO2014201370A1 (en) | 2013-06-14 | 2014-12-18 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
| CN114805527A (zh) | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| BR112017005598A2 (pt) * | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその製剤 |
| KR101652894B1 (ko) * | 2014-12-18 | 2016-09-02 | 가천대학교 산학협력단 | 대장암에 대한 신규 바이오마커 및 그의 용도 |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US9765117B2 (en) | 2015-08-24 | 2017-09-19 | Romek Figa | Peptides for treating cancer |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| SG11202000634UA (en) * | 2017-07-27 | 2020-02-27 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| WO2019195851A1 (en) | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2022183006A1 (en) | 2021-02-25 | 2022-09-01 | Mayo Foundation For Medical Education And Research | Compounds for programmable protein degradation and methods of use for the disease treatment |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| KR102892954B1 (ko) * | 2023-01-12 | 2025-12-01 | (주) 수파드엘릭사 | p53을 활성화하는 펩타이드 및 이를 포함하는 조성물 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| AU4544393A (en) * | 1992-06-26 | 1994-01-24 | Trustees Of Princeton University, The | Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes |
| CA2124595A1 (en) * | 1992-09-30 | 1994-04-14 | Hanswalter Zentgraf | Process for detecting p53-specific antibodies |
| FR2698367B1 (fr) * | 1992-11-02 | 1995-02-17 | Eurobio Lab | Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques. |
| US5532348A (en) * | 1993-07-30 | 1996-07-02 | United States Of America | E6 associated protein and methods of use thereof |
-
1995
- 1995-04-19 US US08/424,957 patent/US5770377A/en not_active Expired - Fee Related
- 1995-07-20 DE DE69533855T patent/DE69533855T2/de not_active Expired - Fee Related
- 1995-07-20 NZ NZ289899A patent/NZ289899A/xx unknown
- 1995-07-20 EP EP95925934A patent/EP0773996B1/de not_active Expired - Lifetime
- 1995-07-20 AU AU29876/95A patent/AU684194B2/en not_active Ceased
- 1995-07-20 JP JP50484096A patent/JP3961015B2/ja not_active Expired - Fee Related
- 1995-07-20 WO PCT/GB1995/001719 patent/WO1996002642A1/en not_active Ceased
- 1995-07-20 AT AT95925934T patent/ATE284959T1/de not_active IP Right Cessation
- 1995-07-20 CA CA002195533A patent/CA2195533A1/en not_active Abandoned
-
1998
- 1998-03-05 US US09/035,686 patent/US6153391A/en not_active Expired - Fee Related
-
2007
- 2007-02-23 JP JP2007043694A patent/JP2007222170A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6153391A (en) | 2000-11-28 |
| JPH10506525A (ja) | 1998-06-30 |
| DE69533855D1 (de) | 2005-01-20 |
| JP2007222170A (ja) | 2007-09-06 |
| JP3961015B2 (ja) | 2007-08-15 |
| AU684194B2 (en) | 1997-12-04 |
| CA2195533A1 (en) | 1996-02-01 |
| EP0773996A1 (de) | 1997-05-21 |
| US5770377A (en) | 1998-06-23 |
| EP0773996B1 (de) | 2004-12-15 |
| AU2987695A (en) | 1996-02-16 |
| DE69533855T2 (de) | 2005-12-08 |
| WO1996002642A1 (en) | 1996-02-01 |
| NZ289899A (en) | 2000-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
| HUP9904023A2 (hu) | Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban | |
| DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
| ATE230757T1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
| ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
| DE69730604D1 (de) | Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen | |
| WO1998026747A3 (en) | Superantigen based methods and compositions for treatment of diseases | |
| DK0942740T3 (da) | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme | |
| DE69324487D1 (de) | Rezeptorbindende region des diphtherietoxius | |
| ATE397621T1 (de) | Hemmer der interaktion zwischen p53 und mdm2 | |
| ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
| EP0709090A3 (de) | Zusammensetzungen zur Behandlung von resistenten Tumoren | |
| NO972451L (no) | Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav | |
| ATE342278T1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| NO972391L (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
| DE69531004D1 (de) | p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES | |
| ATE290315T1 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
| DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
| DE69519602D1 (de) | Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden | |
| DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0773996 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |